The Women's Health Investment Landscape in 2025: What the Numbers Are Telling Us - 7/09/2026

📆 Upcoming Hustle Fund Events

• 🇺🇸 July 23 – Sausalito, CA – Funders & Founders Happy Hour

• 🇺🇸 August 5 – San Francisco, CA – Women Founder & VC Meetup

Wanna volunteer? Join the events team in your city.

📰 Today's Edition: The Women's Health Investment Landscape in 2025: What the Numbers Are Telling Us

Women's health has historically been one of the most underfunded categories in healthcare -- commanding less than 2% of R&D investment despite women comprising over half the global population. That's changing fast. In 2024, $2.6B flowed into women's health globally, a 55% jump from 2023, and 2025 is on pace to match or exceed it. Here's what the current landscape looks like, where capital is flowing, and where the biggest opportunities still remain.

INSIGHT #1: THE FUNDING SURGE IS REAL -- BUT UNEVENLY DISTRIBUTED

The headline numbers are encouraging. Women's health has grown from under 2% of healthcare investment in 2020 to roughly 8.8% of global healthtech funding today. 2024 was a breakthrough year, and H1 2025 is tracking over $1.3B globally even as broader healthtech is having its worst fundraising year in over a decade.

But dig into where that money is going and a pattern emerges: nearly three-quarters of 2025 funding is concentrated in just two segments -- fertility and diagnostics/therapeutics. These are proven categories with clear monetization paths, employer benefit tailwinds, and established exit precedents. It makes sense that capital clusters here.

What that also means: most of the women's health landscape is still dramatically underfunded relative to its actual burden on patients. Pelvic health, family planning, brain health, autoimmune -- these segments are getting fractions of what fertility receives, despite serving enormous patient populations with urgent unmet needs. The investment thesis in femtech right now is partly about the proven categories, but mostly about what comes next.

INSIGHT #2: THE BIGGEST OPPORTUNITY MAY BE THE MOST OVERLOOKED -- AUTOIMMUNE AND CARDIOVASCULAR

Two segments stand out as massive white space: autoimmune health and cardiovascular care.

Autoimmune disease affects nearly 80% women, yet received only about $5M in tracked femtech investment in 2025 to date. Conditions like lupus, rheumatoid arthritis, Hashimoto's, and MS have suffered from late diagnoses, fragmented care, and minimal therapeutic innovation -- despite representing a TAM of over $135B in women-focused therapeutics alone. These are chronic, lifelong conditions with recurring treatment needs. And yet the category is barely on the venture radar.

Cardiovascular disease kills more women every year than all cancers combined -- responsible for 30% of female deaths. The U.S. serviceable market for women's cardiovascular health is estimated at $45-50B. And yet cardiovascular care received just $2M in femtech-specific investment tracked in 2025. Women experience heart disease differently than men -- different symptoms, different progression, different treatment responses -- but most protocols were designed around male patients.

A handful of startups are starting to build in both spaces. These are category-creation plays -- similar to where fertility was a decade ago. The founders willing to build here and the investors willing to back them early are looking at wide-open markets.

INSIGHT #3: EMPLOYER ADOPTION IS BECOMING THE UNLOCK FOR SCALE

One of the most important structural shifts in women's health right now isn't happening in the clinic -- it's happening in HR departments.

Fertility benefits like IVF and egg freezing are now offered by roughly 70% of the largest U.S. employers, up from 42% just a few years ago. Menopause platforms like Midi Health have built insurance-covered programs that plug directly into existing benefit structures. Allara, a hormone-care telehealth platform, has locked in payer contracts across all 50 states with Aetna, BCBS, Cigna, Humana, and UHC. Virtual care platforms are increasingly winning not by convincing individual patients to pay out of pocket, but by becoming a line item in corporate benefits packages.

This matters enormously for investors. The TAM for women's health is often framed as a consumer story -- women paying for their own care. The real scale opportunity is B2B2C: building platforms that employers and payers want to offer as benefits, with reimbursement baked in from day one.

The companies that figured out the employer and payer channel are the ones growing fastest. The ones still trying to win purely on consumer subscription are finding it much harder. If you're building in women's health, the question worth asking early is: how does this become something an employer offers to their workforce?

CONCLUSION

The transformation of women's health from overlooked niche to serious investment category is underway. The capital is coming, the clinical validation is building, and employer and payer adoption is accelerating. But there's still a wide gap between where the money is going and where the greatest unmet need exists.

The categories getting funded today -- fertility, diagnostics, virtual care platforms -- are real businesses with real exits ahead. But the categories barely getting funded -- autoimmune, cardiovascular, pelvic health -- may represent the most asymmetric opportunities available in healthtech right now. These are trillion-dollar markets with almost no institutional capital in them.

At Hustle Fund, we're watching this space closely. The founders building here are early, but the problems they're solving are not.

Until next time,

Dunky, the hippocorn in scrubs

🎥 Watch This